Novel Approaches in the Management of Hepatocellular Carcinoma: From Surveillance to Treatment
A special issue of Current Oncology (ISSN 1718-7729).
Deadline for manuscript submissions: closed (31 May 2022) | Viewed by 14107
Special Issue Editors
Interests: biomarkers; cirrhosis; hepatitis B virus; hepatocellular carcinoma; hepatitis D virus; inflammatory bowel disease; liver fibrosis; non-alcoholic fatty liver disease
Special Issues, Collections and Topics in MDPI journals
Interests: biomarkers; cirrhosis; endoscopic ultrasound; hepatitis B virus; hepatocellular carcinoma; interventional ultrasound; liver fibrosis; non-alcoholic fatty liver disease
Special Issue Information
Dear Colleagues,
Liver cancer is the sixth most common cancer in terms of incidence and the third in terms of mortality worldwide, with approximately 841,000 new cases and 782,000 deaths per year; hepatocellular carcinoma (HCC) represents more than 90% of primary liver cancers. Chronic inflammation that characterizes the natural history of chronic hepatitis leads to fibrosis progression, and, overtime, to cirrhosis, a pre-neoplastic condition at high risk for HCC development. Additionally, the molecular alterations that underlie cirrhosis and dysplastic lesions provide dysplastic cells with proliferative, invasive, and survival advantages moving toward the onset of HCC. It is estimated that one-third of patients with cirrhosis will develop HCC during their lifetime.
Major efforts are underway to improve surveillance strategies for the early detection and even the prediction of HCC development. Novel technologies are available, and omics approaches will allow for the identification of new biomarkers that might improve the surveillance of patients at risk of HCC development. On the other hand, biomarkers will help clinicians to tailor the therapeutic approach beyond current guidelines recommendation, as well as to predict patient outcome. Finally, with the recent approval of new different drugs, including tyrosine kinase inhibitors, monoclonal antibodies and immune checkpoint inhibitors as first- and second-line treatments, the current scenario of HCC therapy is rapidly evolving.
For this Special Issue, we encourage the submission of manuscripts on any aspects of HCC management, from surveillance to diagnosis, and from therapy to prognosis.
Dr. Gian Paolo Caviglia
Dr. Silvia Gaia
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Current Oncology is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2200 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- biomarkers
- cirrhosis
- diagnosis
- HBV
- HCC
- HCV
- immune checkpoint inhibitors
- liver transplant
- liquid biopsy
- loco-regional therapy
- microbiota
- NAFLD/NASH
- next-generation sequencing
- omics
- precision medicine
- prognosis
- surgery
- surveillance
- systemic therapy
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue polices can be found here.
